Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.

Liver toxicity notwithstanding, volrustomig will start a phase 3 lung cancer study versus Keytruda imminently.

However, endometrial cancer remains a small use, and Jemperli has other ways to make a bigger splash.

The limited activity of Reblozyl in myelodysplastic syndromes patients without ringed sideroblasts could help Geron.

Regeneron’s fianlimab could be biopharma’s most potent Lag3 project, and has shown activity in a new melanoma setting